Olav Dajani
About
Olav Dajani is a scholar working on Oncology, Molecular Biology and Hepatology.
According to data from OpenAlex, Olav Dajani has authored 39 papers receiving a total of 718 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 11 papers in Hepatology. Recurrent topics in Olav Dajani's work include Liver physiology and pathology (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Olav Dajani is often cited by papers focused on Liver physiology and pathology (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Protein Kinase Regulation and GTPase Signaling (7 papers). Olav Dajani collaborates with scholars based in Norway, United States and Denmark. Olav Dajani's co-authors include Thoralf Christoffersen, Dagny Sandnes, Magne Refsnes, G. Hege Thoresen, Tormod Kyrre Guren, G. Hege Thoresen, Monica Aasrum, Jens‐Gustav Iversen, Sarina A. Piha‐Paul and Guillem Argilés and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.
In The Last Decade
Olav Dajani
38 papers receiving 704 citations
Peers
Olav Dajani
Zhongsheng Peng United States
Clayton D. Knox United States
Jianjun Jin China
Tianfei Lu China
Germana Cicciarelli Italy
Krishna Seshu Tummala Spain
Paola Biason Italy
Jo-Ting Tsai Taiwan
Linda L. Pelleymounter United States
Steven Strom United States
Citations per year, relative to Olav Dajani Olav Dajani (= 1×)
peers
Zhongsheng Peng
Countries citing papers authored by Olav Dajani
Since
Specialization
Citations
This map shows the geographic impact of Olav Dajani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olav Dajani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olav Dajani more than expected).
Fields of papers citing papers by Olav Dajani
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Olav Dajani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olav Dajani. The network helps show where Olav Dajani may publish in the future.
Co-authorship network of co-authors of Olav Dajani
This figure shows the co-authorship network connecting the top 25 collaborators of Olav Dajani. A scholar is included among the top collaborators of Olav Dajani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olav Dajani. Olav Dajani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2025). Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. Journal of Clinical Oncology. 43(18). 2107–2118.
2.
Vagnildhaug, Ola Magne, Øyvind Salvesen, Trude R. Balstad, et al.. (2025). A comparison of inflammatory markers’ potential to predict weight loss in advanced cancer: a prospective observational study. PubMed. 14(1). 12–20.
3.
Kudo, Masatoshi, Ann‐Lii Cheng, Philippe Merle, et al.. (2024). Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.. Journal of Clinical Oncology. 42(16_suppl). 4109–4109.
4.
Solheim, Tora S., Barry Laird, Trude R. Balstad, et al.. (2024). Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.. Journal of Clinical Oncology. 42(17_suppl). LBA12007–LBA12007.
5.
Westgaard, Arne, et al.. (2024). Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers—Simple Tools Matter. Current Oncology. 31(9). 5462–5471.
6.
Hjermstad, Marianne Jensen, Nina Aass, Sigve Andersen, et al.. (2024). PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life. Palliative Medicine. 38(2). 229–239.
7.
Nes, Andréa Aparecida Gonçalves, Heidi Holmen, Anette Winger, et al.. (2023). Health Care Professionals’ Experiences and Perspectives on Using Telehealth for Home-based Palliative Care: Scoping Review. Journal of Medical Internet Research. 25. e43429–e43429.
8.
Nes, Andréa Aparecida Gonçalves, Heidi Holmen, Anette Winger, et al.. (2021). Health Care Professionals’ Experiences and Perspectives on Using Telehealth for Home-Based Palliative Care: Protocol for a Scoping Review. JMIR Research Protocols. 10(10). e33305–e33305.
9.
Hjermstad, Marianne Jensen, Nina Aass, Sigve Andersen, et al.. (2020). PALLiON – PALLiative care Integrated in ONcology: study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care. Trials. 21(1). 303–303.
10.
Hamfjord, Julian, Tormod Kyrre Guren, Olav Dajani, et al.. (2019). Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Annals of Oncology. 30(7). 1088–1095.
11.
Gupta, Shilpa, Guillem Argilés, Pamela N. Münster, et al.. (2015). A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical Cancer Research. 21(23). 5235–5244.
12.
Müller, K.-M., Monica Aasrum, Olav Dajani, et al.. (2012). Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells. Journal of Experimental & Clinical Cancer Research. 31(1). 72–72.
13.
Dajani, Olav, et al.. (2007). Prostaglandins Enhance Epidermal Growth Factor-Induced DNA Synthesis in Hepatocytes by Stimulation of E Prostanoid 3 and F Prostanoid Receptors. Journal of Pharmacology and Experimental Therapeutics. 322(3). 1044–1050.
14.
Dajani, Olav, Tormod Kyrre Guren, Monica Aasrum, et al.. (2007). Prostaglandin E2 upregulates EGF‐stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes. Journal of Cellular Physiology. 214(2). 371–380.
15.
Dajani, Olav, et al.. (2004). Sustained diacylglycerol accumulation resulting from prolonged G protein-coupled receptor agonist-induced phosphoinositide breakdown in hepatocytes. Journal of Cellular Biochemistry. 94(2). 389–402.
16.
Sandnes, Dagny, et al.. (1999). The Relationship between Activation of Phosphoinositide‐Specific Phospholipase C and Growth Stimulation by Ca2+‐Mobilizing Hormones in Hepatocytes. Pharmacology & Toxicology. 84(5). 234–240.
17.
Dajani, Olav, et al.. (1999). Role of diacylglycerol (DAG) in hormonal induction of S phase in hepatocytes: The DAG-dependent protein kinase C pathway is not activated by epidermal growth factor (EGF), but is involved in mediating the enhancement of responsiveness to EGF by vasopressin, angiotensin II, and norepinephrine. Journal of Cellular Physiology. 180(2). 203–214.
18.
Guren, Tormod Kyrre, et al.. (1996). Epidermal Growth Factor Behaves as a Partial Agonist in Hepatocytes: Effects on DNA Synthesis in Primary Culture and Competition with Transforming Growth Factor α. Growth Factors. 13(3-4). 171–179.
19.
Dajani, Olav, Magne Refsnes, Tormod Kyrre Guren, et al.. (1994). Elevated Glucose Concentrations Inhibit DNA Synthesis and Expression of c-myc in Cultured Hepatocytes. Biochemical and Biophysical Research Communications. 202(3). 1476–1482.
20.
Refsnes, Magne, et al.. (1992). Stimulatory and inhibitory effects of catecholamines on DNA synthesis in primary rat hepatocyte cultures: Role of alpha1‐ and beta‐adrenergic mechanisms. Journal of Cellular Physiology. 151(1). 164–171.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Zhongsheng Peng Breakdown of academic impact, for papers by Clayton D. Knox Breakdown of academic impact, for papers by Jianjun Jin Breakdown of academic impact, for papers by Tianfei Lu Breakdown of academic impact, for papers by Germana Cicciarelli Breakdown of academic impact, for papers by Krishna Seshu Tummala Breakdown of academic impact, for papers by Paola Biason Breakdown of academic impact, for papers by Jo-Ting Tsai Breakdown of academic impact, for papers by Linda L. Pelleymounter Breakdown of academic impact, for papers by Steven Strom